Search results :

Atovaquone

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: P01AX06

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3
Headache 16% - 31% x x x
Cough increased 25% - 31% x x
Nausea 0.6% - 37% x x x
Infection 18% - 22% x x
Diarrhoea 0.2% - 42% x x x
Asthenia 8% - 31% x x x
Body temperature increased 0% - 40% x x x
Rhinitis 5% - 24% x x x
Dyspnoea 15% - 21% x x
Insomnia 10% - 19% x x x
Rash 4% - 46% x x x
Hyperglycaemia 9% - 13% x x x
Dysgeusia 3% - 13% x x x
Abdominal pain 4% - 21% x x x
Hypoglycaemia 1% - 15.5% x x x
Vomiting 1% - 22% x x x
Hyponatraemia 7% - 10% x x x
Pain 9.86% - 10% x x x
Anorexia 7% - 10% x x x
Anxiety 7% - 10% x x x
Dyspepsia 5% - 10% x x x
Hypotension 1% - 10% x x x
Dizziness 3% - 14.1% x x x
Phosphatase alkaline increased 8% x x
Amylase increased 4% - 8% x x x
Creatinine increased 0% - 7% x x x
Sinusitis 5.63% - 7% x x x
Alanine aminotransferase increased 6% x x x
Hyperkalaemia 0% - 5% x x x
Neutropenia 3% - 9% x x x
Pruritus 5% x x x
Leukopenia 4% x x x
Aspartate aminotransferase increased 0% - 5% x x x
Constipation 3% x x x
Anaemia 0% - 9% x x x
Bronchospasm postmarketing, 2% x x x
Cough 1% - 14% x x x
Hypersensitivity postmarketing, 0.8% - 4.8% x x x
Angioedema postmarketing x x x
Erythema multiforme postmarketing x x
Hepatitis postmarketing x x
Methaemoglobinaemia postmarketing x x
Pancreatitis postmarketing x x
Stevens-Johnson syndrome postmarketing x x
Thrombocytopenia postmarketing x x
Urticaria postmarketing x x
Hepatic failure postmarketing x x
Keratopathy postmarketing x x
Throat tightness postmarketing x x x
Skin exfoliation postmarketing x x
Renal impairment postmarketing x x
Eye disorder x x
Gastrointestinal disorder x x
Immune system disorder x x
Influenza x x
Sweating x x
Urinary tract disorder x x
Unspecified disorder of skin and subcutaneous tissue x x
Myalgia x x
Hepatobiliary disease x x
Laboratory test abnormal x x x
Blood and lymphatic system disorders x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

ATOVAQUONE / MEPRON

Side effects:37
Source:Health Canada

ATOVAQUONE

Side effects:62
Source:FDA Structured Product Label

ATOVAQUONE

Side effects:62
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label